Several interactions that occur between tumour necrosis factor (TNF) superfamily members have gained prominence based on studies of animal models of immune function and disease. The interactions ...

Announced development of SL-325, a first-in-class antagonist antibody to DR3, the receptor for TL1A; IND filing expected in Q3'2025 – – Cash ...

Several reports now demonstrate a role for the ligand–receptor interaction of TL1A (also known as TNF ligand superfamily member 15) and DR3 in the pathogenesis of RA, [1–4] thus adding a new ...